Eczema Unmasked

This page contents links to external websites. Please note that the accuracy, completeness and reliability of information contained in these websites is not the responsibility of LEO Pharma UK/IE and the use of these links does not imply any recommendation or endorsement by LEO Pharma UK/IE.

LEO Pharma recognises the important role of working closely with patient advocacy groups to raise awareness of the varied and often significant challenges people face living with dermatological conditions and call for positive change. We are therefore extremely proud to have partnered with the National Eczema Society to commission the ‘Eczema Unmasked’ report, with insights from over 1,000 people affected by the condition.

Eczema Unmasked raises awareness of the extensive and under-recognised impact eczema can have on all aspects of peoples’ lives including impact on people’s physical health, mental health, their quality of life, long-term life opportunities – highlighting the variation in healthcare provision and measures that must be taken to bridge these gaps in care. 

Based on these findings LEO Pharma and the National Eczema Society are calling for the voices of those living with eczema to be strengthened, the development of clinical guidelines and quality standards for adults and adolescents with eczema and lastly, improve access to appropriate care and services.

Click here to download the ‘Eczema Unmasked’ report

Eczema Unmasked report cover

 

Key findings

Eczema can affect physical health: 96% of adults and 95% of children experienced itchy skin, many severely, and 67% of adults and 60% of children have had skin so sore that it bleeds.

Eczema can affect mental health: Almost three quarters of adults (74%) stating it had negatively impacted their mental health and 2/3 (66%) of patients said they were lonely/socially isolated because of their eczema. Despite this, less than half had been offered access to emotional or psychological support to help them to manage this.

Eczema can affect day to day life: 89% of adults said eczema significantly reduced their quality of life and 76% of parents said their child’s quality of life is significantly affected.

Eczema can limit life opportunities: Nearly half of adult responders (49%) said eczema had affected their ability to do paid work.

Accessing care and treatment can be challenging: Nearly a third (29%) of adults, and a third (33%) of parents say they have difficulty obtaining the emollients they need from the NHS, while over a quarter (28%) say the same about challenges accessing biologic treatment.

 

Click here to view a summary of the report

 

LEO Pharma and the National Eczema Society’s ‘Eczema Unmasked’ report aims to better represent the experiences of adults with eczema and serve as a new, robust evidence base to demonstrate how eczema can significantly impact people’s physical health, mental health, their quality of life, long-term life opportunities and access to appropriate care.

 Calls to action: Driving positive change through collaboration

 1. Strengthen the voices of those living with eczema

  • Raise public awareness of life with eczema and dispel the myth that it’s just a minor skin complaint
  • Empower people to talk about their eczema to break out of the isolation
  • Give people confidence to press for the medical care and support they need
  • Provide evidence and deeper understanding of eczema for healthcare professionals to improve patient outcomes through holistic approaches to care                                                            

 2. Develop clinical guidelines and quality standards for adults and adolescents with eczema

  • There are no National Institute for Health and Care Excellence (NICE) guidelines and quality standards to guide diagnosis / management of adults or adolscents living with eczema – impacting on costs to the health economy
  • Absence of frameworks leads to huge variations of care at primary and secondary care level, with healthcare professionals relying on individual knowledge and clinical judgement
  • Greater standardisation in clinical care driven by evidence-based treatment guidelines is desperately needed to improve patient outcomes
  • Frameworks will be critical to guide commissioning decisions and prioritise healthcare resources effectively - ensuring consistent access to optimal care and treatment

​ 3.  Improve access to appropriate care and services

  • Dermatology represents an important part of NHS provision, yet fundamental barriers to accessing appropriate care and services still exist
  • Urgent need to improve knowledge of skin diseases and wider impact on patients within primary care
  • Bridge the gap between specialist and primary care services - patients referred to the right service, in the right place, at the right time, so no patient is left untreated or unsupported
  • Encourage clinicians, commissioners and policymakers to prioritise and fund effective care and services locally to reduce unnecessary variation in care and knowledge

 

“There are no national clinical guidelines and quality standards to guide diagnosis and management of eczema in adolescents or adults, leading to huge variations of care. Greater standardisation in clinical care driven by evidence-based treatment guidelines is desperately needed to improve patient outcomes, guide commissioning decisions and prioritise healthcare resources effectively.”

– Funmi Oluwa, Market Access & External Affairs Director, LEO Pharma UK/IE.

“It’s important to better understand the full impact of living with eczema and for patients to get the treatment and support they need to manage this painful medical condition. These survey responses show just how tough it can be living with eczema.”

– Andrew Proctor, Chief Executive, National Eczema Society

 

The Eczema Unmasked report is a collaboration between the National Eczema Society and LEO Pharma. LEO Pharma has provided core funding, editorial input and undertaken survey-based research to support the development of the report. The content was approved by National Eczema Society and reviewed by LEO Pharma to ensure compliance with the ABPI Code of Practice.